Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03634007 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
A Phase 1 study, sponsored by Lexeo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03634007 is a Phase 1 study that has completed, run by Lexeo Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT03634007, a Phase 1 study, has completed, sponsored by Lexeo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, and moderate dementia due to Alzheimer's disease.
Interventions
- BIOLOGICAL LX1001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03634007
The ClinicalTrials.gov registry entry for NCT03634007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexeo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LX1001 is the first listed.
NCT03634007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03634007 about?
NCT03634007 is a clinical study titled "Gene Therapy for APOE4 Homozygote of Alzheimer's Disease". This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, and moderate dementia due to Alzheimer's...
What is the current status of trial NCT03634007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-11-06. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT03634007?
The interventions under investigation include: LX1001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03634007?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.